US firm launches online patient recruitment tool
Californian marketing company BlueLithium has launched a new web-based solution to help pharma companies overcome the challenges of recruiting patients for clinical trials.
Californian marketing company BlueLithium has launched a new web-based solution to help pharma companies overcome the challenges of recruiting patients for clinical trials.
The US Food and Drug Administration (FDA) has proposed plans to phase out chlorofluorocarbons (CFCs) in metered dose inhalers that contain epinephrine, but the decision could spell the end for some asthma treatments.
Weekly Comment
Following the recent news that pharma heavyweight Pfizer has also been struck by contamination of its HIV drug Viracept (nelfinavir), in-PharmaTechnologist.com spoke to the US Food and Drug Administration (FDA) to find out how far reaching the...
Inside India: special series
Indian drug manufacturers need to rid themselves of their generic mindset in order to evolve and remain competitive for the future.
Biogen Idec has bagged two new partnerships in the past week which will see it involved in the search for new drugs for central nervous system (CNS) and inflammatory ailments.
DBV Technologies is advancing into the realm of allergy treatment and vaccine delivery using its Viaskin technology, which has already proved successful as an allergy diagnostic.
Wyatt Technologies has launched a new instrument that automates protein aggregation measurement for use in all areas of the pharmaceutical industry from drug development to quality control (QC).
Bristol-Myers Squibb (BMS) will pay up to $490m (€348m) for Adnexus Therapeutics, as it continues its transformation into a biopharmaceutical company and strengthens its oncology pipeline.
UK firm Protherics has inked a deal with a Korean partner allowing the company to make use of its temperature sensitive sustained release drug delivery system.
A bill proposing stricter import regulations has been presented to Congress, as fears over imported food products show no sign of diminishing.